Skip to main content Accessibility help
Hostname: page-component-56f9d74cfd-w6k7h Total loading time: 0.751 Render date: 2022-06-26T00:43:32.409Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "useRatesEcommerce": false, "useNewApi": true }

Book contents

17 - Amisulpride, Asenapine, Lurasidone, Brexpiprazole, Cariprazine

Published online by Cambridge University Press:  19 October 2021

Jonathan M. Meyer
University of California, San Diego
Stephen M. Stahl
University of California, Riverside and San Diego
Get access


The psychopharmacology field is moving toward a mechanism-based nomenclature to replace outmoded descriptors of molecules with multiple pharmacological properties. In addition to publications covering these efforts [15–17], a Neuroscience-Based Nomenclature website was created ( where one can download a free smartphone app, and which posts twice-yearly glossary updates in May and September. For the sake of simplicity, the term second-generation antipsychotic (SGA) will be used in this chapter, but the antipsychotics described herein have a range of pharmacologic properties, and a wide variety of kinetic profiles. Moreover, with the exception of transdermal asenapine and cariprazine, the SGAs presented in this chapter represent a group that are generally available worldwide.

The Clinical Use of Antipsychotic Plasma Levels
Stahl's Handbooks
, pp. 337 - 371
Publisher: Cambridge University Press
Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)


Sparshatt, A., Taylor, D., Patel, M. X., et al. (2009). Amisulpride – dose, plasma concentration, occupancy and response: implications for therapeutic drug monitoring. Acta Psychiatr Scand, 120, 416428.
Ishigooka, J., Iwashita, S., Higashi, K., et al. (2018). Pharmacokinetics and safety of brexpiprazole following multiple-dose administration to Japanese patients with schizophrenia. J Clin Pharmacol, 58, 7480.
Periclou, A., Willavize, S., Jaworowicz, D., et al. (2020). Relationship between plasma concentrations and clinical effects of cariprazine in patients with schizophrenia or bipolar mania. Clin Transl Sci, 13, 362371.
Loebel, A., Silva, R., Goldman, R., et al. (2016). Lurasidone dose escalation in early nonresponding patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry, 77, 16721680.
FDA Center for Drug Evaluation and Research (2015). Cariprazine pharmacology/toxicology NDA review and evaluation.
Findling, R. L., Goldman, R., Chiu, Y. Y., et al. (2015). Pharmacokinetics and tolerability of lurasidone in children and adolescents with psychiatric disorders. Clin Ther, 37, 27882797.
Schmitt, U., Abou El-Ela, A., Guo, L. J., et al. (2006). Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp). J Neural Transm (Vienna), 113, 787801.
O’Brien, F. E., Dinan, T. G., Griffin, B. T., et al. (2012). Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings. Br J Pharmacol, 165, 289312.
Bartlett, J. A. and van der Voort Maarschalk, K. (2012). Understanding the oral mucosal absorption and resulting clinical pharmacokinetics of asenapine. AAPS PharmSciTech, 13, 11101115.
Allergan USA Inc. (2017). Saphris package insert. Irvine, CA.
Noven Therapeutics LLC (2020). Secuado package insert. Miami, FL.
Otsuka America Pharmaceutical Inc. (2020). Rexulti package insert. Rockville, MD.
Allergan USA Inc. (2019). Vraylar package insert. Madison, NJ.
Nakamura, T., Kubota, T., Iwakaji, A., et al. (2016). Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment). Drug Des Devel Ther, 10, 327338.
Blier, P., Oquendo, M. A., and Kupfer, D. J. (2017). Progress on the Neuroscience-Based Nomenclature (NbN) for Psychotropic Medications. Neuropsychopharmacology, 42, 19271928.
Uchida, H. (2018). Neuroscience-based Nomenclature: what is it, why is it needed, and what comes next? Psychiatry Clin Neurosci, 72, 5051.
Siafis, S., Davis, J. M., and Leucht, S. (2020). Antipsychotic drugs: from ‘major tranquilizers’ to Neuroscience-based-Nomenclature. Psychol Med, 13.
Correll, C. U., Jain, R., Meyer, J. M., et al. (2019). Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation. Neuropsychiatr Dis Treat, 15, 25372550.
Vanda Pharmaceuticals Inc. (2018). Fanapt package insert. Washington, DC.
Komossa, K., Rummel-Kluge, C., Hunger, H., et al. (2009). Sertindole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev, CD006752.
Beedham, C., Miceli, J. J., and Obach, R. S. (2003). Ziprasidone metabolism, aldehyde oxidase, and clinical implications. J Clin Psychopharmacol, 23, 229232.
Roerig Division of Pfizer Inc. (2020). Geodon package insert. New York.
Asmal, L., Flegar, S. J., Wang, J., et al. (2013). Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev, CD006625.
Vanasse, A., Blais, L., Courteau, J., et al. (2016). Comparative effectiveness and safety of antipsychotic drugs in schizophrenia treatment: a real-world observational study. Acta Psychiatr Scand, 134, 374384.
Intra-Cellular Therapies Inc. (2019). Caplyta package insert. New York.
Vyas, P., Hwang, B. J., and Brasic, J. R. (2019). An evaluation of lumateperone tosylate for the treatment of schizophrenia. Expert Opin Pharmacother, 30, 17.
Meyer, J. M. (2020). Lumateperone for schizophrenia. Curr Psychiatr, 19, 3339.
Huhn, M., Nikolakopoulou, A., Schneider-Thoma, J., et al. (2019). Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet, 394, 939951.
Kahn, R. S., Winter van Rossum, I., Leucht, S., et al. (2018). Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. Lancet Psychiatry, 5, 797807.
Delcker, A., Schoon, M. L., Oczkowski, B., et al. (1990). Amisulpride versus haloperidol in treatment of schizophrenic patients – results of a double-blind study. Pharmacopsychiatry, 23, 125130.
Abbas, A. I., Hedlund, P. B., Huang, X.-P., et al. (2009). Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology, 205, 119128.
Meyer, J. M., Loebel, A. D., and Schweizer, E. (2009). Lurasidone: a new drug in development for schizophrenia. Expert Opin Investig Drugs, 18, 17151726.
Meyer, J. M. (2018). Pharmacotherapy of psychosis and mania. In Brunton, L. L., Hilal-Dandan, R. and Knollmann, B. C., eds., Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 13th edn. Chicago, IL: McGraw-Hill, pp. 279302.
Schoemaker, H., Claustre, Y., Fage, D., et al. (1997). Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther, 280, 8397.
Stahl, S. M. (2017). Drugs for psychosis and mood: unique actions at D3, D2, and D1 dopamine receptor subtypes. CNS Spectr, 22, 375384.
Kahn, R. S., Fleischhacker, W. W., Boter, H., et al. (2008). Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet, 371, 10851097.
Hartter, S., Huwel, S., Lohmann, T., et al. (2003). How does the benzamide antipsychotic amisulpride get into the brain? – An in vitro approach comparing amisulpride with clozapine. Neuropsychopharmacology, 28, 19161922.
Wang, R., Sun, X., Deng, Y. S., et al. (2018). ABCB1 1199G > A polymorphism impacts transport ability of P-gp-mediated antipsychotics. DNA Cell Biol, 37, 325329.
Arrowtex Pharmaceuticals (2019). Amisulpride package insert. Macquarie Park, NSW, Australia.
Bergemann, N., Kopitz, J., Kress, K. R., et al. (2004). Plasma amisulpride levels in schizophrenia or schizoaffective disorder. Eur Neuropsychopharmacol, 14, 245250.
Muller, M. J., Eich, F. X., Regenbogen, B., et al. (2009). Amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder. J Psychopharmacol, 23, 278286.
Schoretsanitis, G., Kane, J. M., Correll, C. U., et al. (2020). Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the American Society of Clinical Psychopharmacology (ASCP) and the Therapeutic Drug Monitoring (TDM) Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP). J Clin Psychiatry, 81,
Puech, A., Fleurot, O., and Rein, W. (1998). Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group. Acta Psychiatr Scand, 98, 6572.
Muller, M. J., Regenbogen, B., Hartter, S., et al. (2007). Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia. J Psychiatr Res, 41, 673679.
Mota, N. E., Lima, M. S., and Soares, B. G. (2002). Amisulpride for schizophrenia. Cochrane Database Syst Rev, 2002, CD001357.
Linden, M., Scheel, T., and Xaver Eich, F. (2004). Dosage finding and outcome in the treatment of schizophrenic inpatients with amisulpride: results of a drug utilization observation study. Hum Psychopharmacol, 19, 111119.
Shahid, M., Walker, G. B., Zorn, S. H., et al. (2009). Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol, 23, 6573.
Citrome, L. (2014). Asenapine review, part I: chemistry, receptor affinity profile, pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol, 10, 893903.
Vieta, E. and Montes, J. M. (2018). A review of asenapine in the treatment of bipolar disorder. Clin Drug Investig, 38, 8799.
El-Mallakh, R. S., Nuss, S., Gao, D., et al. (2020). Asenapine in the treatment of bipolar depression. Psychopharmacol Bull, 50, 818.
Koytchev, R., Alken, R. G., McKay, G., et al. (1996). Absolute bioavailability of oral immediate and slow release fluphenazine in healthy volunteers. Eur J Clin Pharmacol, 51, 183187.
Andree, B., Halldin, C., Vrijmoed-de Vries, M., et al. (1997). Central 5-HT2A and D2 dopamine receptor occupancy after sublingual administration of ORG 5222 in healthy men. Psychopharmacology, 131, 339345.
Carrithers, B. and El-Mallakh, R. S. (2020). Transdermal asenapine in schizophrenia: a systematic review. Patient Prefer Adherence, 14, 15411551.
Seager, H. (1998). Drug-delivery products and the Zydis fast-dissolving dosage form. J Pharm Pharmacol, 50, 375382.
Pillinger, T., McCutcheon, R. A., Vano, L., et al. (2020). Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry, 7, 6477.
Citrome, L. (2014). Asenapine review, part II: clinical efficacy, safety and tolerability. Expert Opin Drug Saf, 13, 803830.
Dogterom, P., Riesenberg, R., de Greef, R., et al. (2018). Asenapine pharmacokinetics and tolerability in a pediatric population. Drug Des Develop Ther, 12, 26772693.
de Greef, R., Maloney, A., Olsson-Gisleskog, P., et al. (2011). Dopamine D2 occupancy as a biomarker for antipsychotics: quantifying the relationship with efficacy and extrapyramidal symptoms. AAPS Journal, 13, 121130.
Food and Drug Administration Center for Drug Evaluation and Research (2009). Asenapine medical review.
Hiemke, C., Bergemann, N., Clement, H. W., et al. (2018). Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry, 51, 962.
Chapel, S., Hutmacher, M. M., Haig, G., et al. (2009). Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation. J Clin Pharmacol, 49, 12971308.
Ward, H. B., Yudkoff, B. L., and Fromson, J. A. (2019). Lurasidone malabsorption following bariatric surgery: a case report. J Psychiatr Pract, 25, 313317.
Baldessarini, R. J., Tondo, L., and Vazquez, G. H. (2019). Pharmacological treatment of adult bipolar disorder. Mol Psychiatry, 24, 198217.
Sunovion Pharmaceuticals Inc. (2019). Latuda package insert. Marlborough, MA.
Wong, D. F., Kuwabara, H., Brašicć, J. R., et al. (2013). Determination of dopamine D2 receptor occupancy by lurasidone using positron emission tomography in healthy male subjects. Psychopharmacology, 229, 245252.
Potkin, S. G., Keator, D. B., Kesler-West, M. L., et al. (2014). D2 receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder. CNS Spectr, 19, 176181.
Maeda, K., Lerdrup, L., Sugino, H., et al. (2014). Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin–dopamine activity modulator. J Pharmacol Exp Ther, 350, 605614.
Maeda, K., Sugino, H., Akazawa, H., et al. (2014). Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin–dopamine activity modulator. J Pharmacol Exp Ther, 350, 589604.
Tadori, Y., Forbes, R. A., McQuade, R. D., et al. (2011). In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors. Eur J Pharmacol, 668, 355365.
McEvoy, J. and Citrome, L. (2016). Brexpiprazole for the treatment of schizophrenia: a review of this novel serotonin–dopamine activity modulator. Clin Schizophr Relat Psychoses, 9, 177186.
Ward, K. and Citrome, L. (2019). Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy. Neuropsychiatr Dis Treat, 15, 247257.
Girgis, R. R., Forbes, A., Abi-Dargham, A., et al. (2020). A positron emission tomography occupancy study of brexpiprazole at dopamine D2 and D3 and serotonin 5-HT1A and 5-HT2A receptors, and serotonin reuptake transporters in subjects with schizophrenia. Neuropsychopharmacology, 45, 786792.
Takeuchi, H. and Remington, G. (2013). A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder. Psychopharmacology (Berl), 228, 175185.
Wong, D. F., Malikaarjun, S., Raoufinia, A., et al. (2011). 619. A phase I, open-label PET study of the pharmacokinetics, tolerability and D2/D3 striatal occupancy of single-dose oral OPC-34712 in healthy subjects. Biol Psychiatry, 69, 187s.
Food and Drug Administration Center for Drug Evaluation and Research (2015). Cariprazine pharmacology/toxicology NDA review and evaluation.
Girgis, R. R., Slifstein, M., D’Souza, D., et al. (2016). Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO. Psychopharmacology (Berl), 233, 35033512.
Otsuka America Pharmaceutical Inc. (2020). Abilify package insert. Rockville, MD.
Németh, G., Laszlovszky, I., Czobor, P., et al. (2017). Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet, 389, 11031113.
Ragguett, R. M. and McIntyre, R. S. (2019). Cariprazine for the treatment of bipolar depression: a review. Expert Rev Neurother, 19, 317323.

Save book to Kindle

To save this book to your Kindle, first ensure is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the or variations. ‘’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats